AstraZeneca COVID-19 vaccine Vaxzevria is associated with a very rare risk of a condition called thrombosis with thrombocytopenia syndrome, or TTS. 

TTS involves blood clots (thrombosis) along with low platelet levels (thrombocytopenia), and occurs around 4-28 days after vaccination. It is currently estimated to affect around 6 people per million doses. To date, almost all reported cases were after the first dose of the vaccine. 

Several resources are available to provide information to immunisation providers about TTS following vaccination with COVID-19 Vaccine AstraZeneca.

NCIRS COVID-19 vaccines: Frequently asked questions

We have answered commonly asked questions about thrombosis with thrombocytopenia syndrome following COVID-19 Vaccine AstraZeneca on our COVID-19 vaccines: Frequently asked questions webpage. Access these and other questions and answers about COVID-19 vaccines here.

ATAGI statements and advices
Australian Government Department of Health resources
Therapeutic Goods Administration advisories 
Others
Last updated September 2021